EP1144 Stage IV choriocarcinoma: case report and review of literature

Autor: A Veiga-Fernández, Já Arranz, P Rincón-Olbes, C García-Díaz, EM Mendizábal-Vicente, S Lizarraga-Bonelli

Publikováno v: ePoster.

Introduction/Background Choriocarcinoma is the most aggressive histologic type of gestational trophoblastic neoplasia (GTN). It consists of invasive, highly vascular and anaplastic trophoblastic tissue made up of cytotrophoblasts and syncytiotrophobl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e4aebe4342ff571100716db77b047fc
https://doi.org/10.1136/ijgc-2019-esgo.1185

Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.

Autor: Galsky MD; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: matthew.galsky@mssm.edu., Guan X; Genentech Inc., South San Francisco, CA 94080, USA., Rishipathak D; Genentech Inc., South San Francisco, CA 94080, USA., Rapaport AS; Genentech Inc., South San Francisco, CA 94080, USA., Shehata HM; Genentech Inc., South San Francisco, CA 94080, USA., Banchereau R; Genentech Inc., South San Francisco, CA 94080, USA., Yuen K; Genentech Inc., South San Francisco, CA 94080, USA., Varfolomeev E; Genentech Inc., South San Francisco, CA 94080, USA., Hu R; Genentech Inc., South San Francisco, CA 94080, USA., Han CJ; Genentech Inc., South San Francisco, CA 94080, USA., Li H; Hoffmann-La Roche Ltd, Mississauga, ON, Canada., Liang Y; Genentech Inc., South San Francisco, CA 94080, USA., Vucic D; Genentech Inc., South San Francisco, CA 94080, USA., Wang L; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; GeneDx, Stamford, CT, USA., Zhu J; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; GeneDx, Stamford, CT, USA., Yu H; GeneDx, Stamford, CT, USA., Herbst RH; Immunai, New York, NY, USA., Hajaj E; Immunai, New York, NY, USA., Kiner E; Immunai, New York, NY, USA., Bamias A; National and Kapodistrian University of Athens, Athens, Greece., De Santis M; Department of Urology, Charité - Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria., Davis ID; Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia., Arranz JÁ; Gregorio Marañón General University Hospital, Madrid, Spain., Kikuchi E; St. Marianna University School of Medicine, Kawasaki, Japan., Bernhard S; Roche Products Ltd, Welwyn Garden City, UK., Williams P; Genentech Inc., South San Francisco, CA 94080, USA., Lee C; Roche Products Ltd, Welwyn Garden City, UK., Mellman I; Genentech Inc., South San Francisco, CA 94080, USA., Sanjabi S; Genentech Inc., South San Francisco, CA 94080, USA., Johnston R; Genentech Inc., South San Francisco, CA 94080, USA., Black PC; Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada., Grande E; MD Anderson Cancer Center Madrid, Madrid, Spain., Mariathasan S; Genentech Inc., South San Francisco, CA 94080, USA. Electronic address: mariathasan.sanjeev@gene.com.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2024 Feb 20; Vol. 5 (2), pp. 101393. Date of Electronic Publication: 2024 Jan 26.

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.

Autor: Grande E; Hospital Ramon y Cajal, Madrid, Spain., Bamias A; National & Kapodistrian University of Athens, Athens, Greece., Galsky MD; Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY, USA., Kikuchi E; Keio University Hospital, Tokyo, Japan., Davis ID; Monash University, Melbourne, Australia.; Eastern Health Clinical School, Melbourne, Australia., Arranz JÁ; Gregorio Maranon Hospital, Madrid, Spain., Rezazadeh Kalebasty A; Norton Cancer Institute, Louisville, KY, USA., Garcia Del Muro X; Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain., Park SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy., Alekseev B; Research Oncology Institute, Tomsk, Russia., Mencinger M; Institute of Oncology Ljubljana, Ljubljana, Slovenia., Izumi K; Kanazawa University Hospital, Kanazawa, Japan., Puente J; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, CIBERONC, Madrid, Spain., Li JR; Taichung Veterans General Hospital, Taichung, Taiwan., Bernhard S; Roche Products Limited, Welwyn Garden City, UK., Nicholas A; Genentech Inc., South San Francisco, CA, USA., Telliez J; F. Hoffmann-La Roche Ltd., Basel, Switzerland., De Santis M; Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany.; Department of Urology, Medical University Vienna, Vienna, Austria.

Publikováno v: European urology open science [Eur Urol Open Sci] 2023 Nov 04; Vol. 58, pp. 28-36. Date of Electronic Publication: 2023 Nov 04 (Print Publication: 2023).

Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis.

Autor: Arranz-Herrero J; Transplant Immunology Unit, Microbiology National Center, Instituto de Salud Carlos III, Madrid, Spain; Microbiology Section, Department of Pharmaceutical Science and Health, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, Spain; Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Díez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain., Presa J; Independent researcher, Madrid, Spain., Rius-Rocabert S; Microbiology Section, Department of Pharmaceutical Science and Health, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, Spain; Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Díez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain; CEMBIO (Centre for Metabolomics and Bioanalysis), Pharmacy School, San Pablo CEU University, Madrid, Spain., Utrero-Rico A; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA., Arranz-Arija JÁ; Medical Oncology Department, Gregorio Marañón University Hospital, Madrid, Spain., Lalueza A; Internal Medicine Department, Hospital 12 de Octubre, Madrid, Spain., Escribese MM; Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Díez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain., Ochando J; Transplant Immunology Unit, Microbiology National Center, Instituto de Salud Carlos III, Madrid, Spain; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA., Soriano V; Infectious Diseases Unit, UNIR Health Science School & Medical Center, Madrid, Spain., Nistal-Villan E; Microbiology Section, Department of Pharmaceutical Science and Health, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, Spain; Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Díez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain. Electronic address: estanislao.nistalvillan@ceu.es.

Publikováno v: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2023 Jun; Vol. 131, pp. 173-179. Date of Electronic Publication: 2023 Apr 07.

The Spanish Scientific Societies before the ESC 2021 guidelines on vascular disease prevention: Generalizing the measurement of albuminuria to identify vascular risk and prevent vascular disease.

Autor: Ortiz A; Sociedad Española de Nefrología (S.E.N.); Servicio de Nefrología, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain., Quiroga B; Sociedad Española de Nefrología (S.E.N.); Servicio de Nefrología, IIS-La Princesa, Hospital Universitario de la Princesa, Madrid, Spain. Electronic address: borjaqg@gmail.com., Díez J; Sociedad Española de Nefrología (S.E.N.); Center of Applied Medical Research and School of Medicine, University of Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red de la Enfermedades Cardiovasculares (CIBERCV), Carlos III Institute of Health, Madrid, Spain., Escalada San Martín FJ; Servicio de Endocrinología, Clínica Universidad de Navarra, Pamplona, Spain; Sociedad Española de Endocrinología y Nutrición (SEEN)., Ramirez L; Servicio de Angiología y Cirugía Vascular, Hospital Universitario de la Paz, Madrid, Spain; Sociedad Española de Angióloga y Cirugía Vascular (SEACV)., Pérez Maraver M; Servicio de Endocrinología, Hospital Universitari Bellvitge, Barcelona, Spain; Sociedad Española de Diabetes (SED)., Martínez-Berganza Asensio ML; Centro de Salud Ensanche de Vallecas, Madrid, Spain; Sociedad Española de Médicos de Atención Primaria (SEMERGEN)., Arranz Arija JÁ; Servicio de Oncología, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Sociedad Española de Oncología Médica (SEOM)., Alvarez-Ossorio Fernández JL; Hospital Universitario Puerta del Mar, Cádiz, Spain; Asociación Española de Urología (AEU)., Córdoba R; Servicio de Hematología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; Sociedad Española de Hematología y Hemoterapia (SEHH)., Brotons Muntó F; Centro de Salud Trinitat, Valencia, Spain; Sociedad Española de Medicina de Familia y Comunitaria (semFYC)., Cancelo Hidalgo MJ; Servicio de Ginecología y Obstetricia, Hospital Universitario de Guadalajara, Universidad de Alcalá, Guadalajara, Spain; Sociedad Española de Ginecología y Obstetricia (SEGO)., Carles Reverter J; Servicio de Hematología, Hospital Clínic, Barcelona, Spain; Sociedad Española de Trombosis y Hemostasia (SETH)., Plasencia-Rodríguez C; Servicio de Reumatología, Hospital Universitario La Paz, Madrid, Spain; Sociedad Española de Reumatología (SER)., Carretera Gómez J; Servicio de Medicina Interna, Hospital Universitario de Badajoz, Badajoz, Spain; Sociedad Española de Medicina Interna (SEMI)., Guijarro C; Servicio de Medicina Interna, Hospital Universitario Fundación Alcorcón - Universidad Rey Juan-Carlos, Madrid, Spain; Sociedad Española de Arterioesclerosis (SEA)., Freijo Guerrero MDM; Sociedad Española de Nefrología (S.E.N.); Servicio de Neurología, Hospital de Cruces, Baracaldo, Spain; En representación del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología., de Sequera P; Sociedad Española de Nefrología (S.E.N.); Servicio de Nefrología, Hospital Universitario Infanta Leonor, Universidad Complutense De Madrid, Madrid, Spain.

Publikováno v: Nefrologia [Nefrologia (Engl Ed)] 2023 Mar-Apr; Vol. 43 (2), pp. 245-250. Date of Electronic Publication: 2023 Jul 03.